Ключові слова
коронавірусна інфекція, серцево-судинні захворювання, патогенез, діагностика, Європейське товариство кардіологів.
Як цитувати
Katerenchuk, I. (2022). Огляд основних положень рекомендацій Європейського товариства кардіологів із діагностики та лікування серцево-судинних захворювань під час пандемії COVID-19 (2021). Частина 2: Лікування та подальші спостереження. Практикуючий лікар, (1), 17-25. Retrieved із https://plr.com.ua/index.php/journal/article/view/686
Анотація
У статті наведено другу частину огляду основних положень рекомендацій Європейського товариства кардіологів із діагностики та лікування серцево-судинних захворювань під час пандемії COVID-19 (2021). Висвітлено питання шляхів лікування та подальшого спостереження пацієнтів після перенесеної коронавірусної інфекції.
Посилання
1. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1 — epidemiology, pathophysiology, and diagnosis. The Task Force for the management of COVID-19 of the European Society of Cardiology Received 23 April 2021; revised 8 July 2021; editorial decision 10 September 2021; accepted 13 September 2021. Режим доступу: https://pubmed.ncbi.nlm.nih.gov/34791154/
2. Agostini ML, Andres EL, Sims AC et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221-00218.
3. Albert CL, Carmona-Rubio AE, Weiss AJ, Procop GG, Starling RC, Rodriguez ER. The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2. Circulation. 2020;142:1865-1870.
4. Basso C, Leone O, Rizzo S et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41:3827-3835.
5. Boulware DR, Pullen MF, Bangdiwala AS et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517-525.
6. Chen D, Li X, Song Q et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China JAMA Netw Open. 2020;3:e2011122.
7. Cavalcanti AB, Zampieri FG, Rosa RG et al. Coalition COVID-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19. N Engl J Med. 2020;383:2041-2052.
8. Choudry FA, Hamshere SM, Rathod KS et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76:1168-1176.
9. De Rosa S, Spaccarotella C, Basso C et al. Società Italiana di Cardiologia and the CCU Academy investigators group . Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083-2088.
10. de Wit E, Feldmann F, Cronin J et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117:6771-6776.
11. Furuhashi M, Moniwa N, Mita T et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15-21.
12. Group RC, Horby P, Mafham M et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030-2040.
13. Guan WJ, Ni ZY, Hu Y et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
14. Horby PW, Campbell M, Spata E et al. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021:2021.2005.2018.21257267.
15. Ibanez B, James S, Agewall S. et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.
2. Agostini ML, Andres EL, Sims AC et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221-00218.
3. Albert CL, Carmona-Rubio AE, Weiss AJ, Procop GG, Starling RC, Rodriguez ER. The enemy within: sudden-onset reversible cardiogenic shock with biopsy-proven cardiac myocyte infection by severe acute respiratory syndrome coronavirus 2. Circulation. 2020;142:1865-1870.
4. Basso C, Leone O, Rizzo S et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41:3827-3835.
5. Boulware DR, Pullen MF, Bangdiwala AS et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517-525.
6. Chen D, Li X, Song Q et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China JAMA Netw Open. 2020;3:e2011122.
7. Cavalcanti AB, Zampieri FG, Rosa RG et al. Coalition COVID-19 Brazil I Investigators. Hydroxychloroquine with or without azithromycin in mild-tomoderate Covid-19. N Engl J Med. 2020;383:2041-2052.
8. Choudry FA, Hamshere SM, Rathod KS et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020;76:1168-1176.
9. De Rosa S, Spaccarotella C, Basso C et al. Società Italiana di Cardiologia and the CCU Academy investigators group . Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083-2088.
10. de Wit E, Feldmann F, Cronin J et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020;117:6771-6776.
11. Furuhashi M, Moniwa N, Mita T et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15-21.
12. Group RC, Horby P, Mafham M et al. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030-2040.
13. Guan WJ, Ni ZY, Hu Y et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
14. Horby PW, Campbell M, Spata E et al. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021:2021.2005.2018.21257267.
15. Ibanez B, James S, Agewall S. et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119-177.
Завантаження
Дані завантаження ще не доступні.